Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Taylor

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Clinical Pharmacokinetics|September 21, 2006
Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisersTimothy J Taylor, Kelly Diringer, Tanya Russell, et al.
JMIR Public Health and Surveillance|February 16, 2021
Fostering Engagement With Health and Housing Innovation: Development of Participant Personas in a Social Housing CohortAndrew James Williams, Tamaryn Menneer, Mansi Sidana, et al.
Biopharmaceutics & Drug Disposition|September 1, 2006
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomesAmit S Kalgutkar, Heather L Hatch, Frederick Kosea, et al.
Journal of Clinical Pharmacology|April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age RangeMichael J Hanley, Diane R Mould, Timothy J Taylor, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|May 31, 2021
Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detectionThibaut Jombart, Stéphane Ghozzi, Dirk Schumacher, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2011
Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535Allen J Duplantier, Mark A Dombroski, Chakrapani Subramanyam, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2006
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical developmentKim F McClure, Michael A Letavic, Amit S Kalgutkar, et al.
Environmental Health Perspectives|November 10, 2020
Guidelines for Modeling and Reporting Health Effects of Climate Change Mitigation ActionsJeremy J Hess, Nikhil Ranadive, Chris Boyer, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Clinical Pharmacokinetics|September 21, 2006
Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisersTimothy J Taylor, Kelly Diringer, Tanya Russell, et al.
JMIR Public Health and Surveillance|February 16, 2021
Fostering Engagement With Health and Housing Innovation: Development of Participant Personas in a Social Housing CohortAndrew James Williams, Tamaryn Menneer, Mansi Sidana, et al.
Biopharmaceutics & Drug Disposition|September 1, 2006
Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomesAmit S Kalgutkar, Heather L Hatch, Frederick Kosea, et al.
Journal of Clinical Pharmacology|April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age RangeMichael J Hanley, Diane R Mould, Timothy J Taylor, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|May 31, 2021
Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detectionThibaut Jombart, Stéphane Ghozzi, Dirk Schumacher, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2011
Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535Allen J Duplantier, Mark A Dombroski, Chakrapani Subramanyam, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2006
Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical developmentKim F McClure, Michael A Letavic, Amit S Kalgutkar, et al.
Environmental Health Perspectives|November 10, 2020
Guidelines for Modeling and Reporting Health Effects of Climate Change Mitigation ActionsJeremy J Hess, Nikhil Ranadive, Chris Boyer, et al.
Pageof 2